Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Cash & Current Investments (2016 - 2026)

Corvus Pharmaceuticals' Cash & Current Investments history spans 12 years, with the latest figure at $236.7 million for Q1 2026.

  • Quarterly Cash & Current Investments rose 4635.23% to $236.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $236.7 million through Mar 2026, up 4635.23% year-over-year, with the annual reading at $56.8 million for FY2025, 9.21% up from the prior year.
  • Cash & Current Investments came in at $236.7 million for Q1 2026, up from $56.8 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $236.7 million in Q1 2026 to a low of $2.9 million in Q3 2025.
  • The 5-year median for Cash & Current Investments is $14.7 million (2025), against an average of $31.9 million.
  • Year-over-year, Cash & Current Investments plummeted 79.26% in 2022 and then surged 4635.23% in 2026.
  • Corvus Pharmaceuticals' Cash & Current Investments stood at $13.2 million in 2022, then dropped by 4.1% to $12.6 million in 2023, then skyrocketed by 311.76% to $52.0 million in 2024, then grew by 9.21% to $56.8 million in 2025, then soared by 317.12% to $236.7 million in 2026.
  • Per Business Quant, the three most recent readings for CRVS's Cash & Current Investments are $236.7 million (Q1 2026), $56.8 million (Q4 2025), and $2.9 million (Q3 2025).